Table 1 Characteristics of randomized controlled clinical trials in the meta-analysis
First author | Year | Study | NCT number | Center | Inclusion period | Total number | TPF/PF | Follow-up mean (month) | Induction Chemotherapy (IC) | Treatment after IC | Performance status | Median age(year) | Male (%) | Unresectable (%) | Jaded score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hitt | 2005 | / | / | SP | 1998-2001 | 382 | 189/193 | 23.2 | paclitaxel+PF vs PF | chemoradiotherapy | ECOG 0-1 | TPF 56/PF 55 | TPF 94/PF 94 | TPF 64/PF 66 | 4 |
Hitt | 2014 | TTCC | NCT00261703 | SP | 2002-2007 | 439 | 155/156 | 23.8/22.1 | docetaxel+PF vs PF | chemoradiotherapy | ECOG 0-1 | TPF 58/PF 58 | TPF 94/PF 93 | 100 | 4 |
Lorch | 2011 | TAX324 | NCT00273546 | US | 1999-2003 | 501 | 255/246 | 72.2 | docetaxel+PF vs PF | chemoradiotherapy | WHO-PS 0-1 | TPF 55/PF 56 | TPF 84/PF 83 | TPF 67/PF 64 | 4 |
Posner | 2007 | TAX324 | NCT00273546 | US | 1999-2003 | 501 | 255/246 | 42 | docetaxel+PF vs PF | chemoradiotherapy | WHO-PS 0-1 | TPF 55/PF 56 | TPF 84/PF 83 | TPF 67/PF 64 | 4 |
Vermorken | 2007 | EORTC 24971/TAX323 | NCT00003888 | BL | 1999-2002 | 358 | 177/181 | 32.5 | docetaxel+PF vs PF | radiotherapy | WHO-PS 0-1 | TPF 53/PF 53 | TPF 90/PF 90 | 100 | 4 |
Vermorken | 2011 | EORTC 24971/TAX323 | NCT00003888 | BL | / | 308 | 156/152 | 103.2 | docetaxel+PF vs PF | radiotherapy | / | / | / | 100 | 3 |
Pointreau | 2009 | GORTEC | NCT00169182 | FR | 2000-2005 | 213 | 110/103 | 36 | docetaxel+PF vs PF | radiotherapy and/or chemoradiotherapy | Karnofsky PS 100-80 | TPF 57/PF 56 | TPF 92/PF 94 | / | 4 |